Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Paul M. Barr, Stephen Smith, Mark Roschewski, Susan M. O’Brien, Jeff P. Sharman, Jason M. Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen Spurgeon

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
JournalLeukemia and Lymphoma
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this